<b>Format of Initial Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=''1px''><tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> <td><b>Details</b></td> ....
VENUSREM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Venus Remedies Ltd has filed its annual regulatory disclosure with BSE and NSE confirming that it does NOT qualify as a 'Large Corporate' as of 31st March 2025. The filing was made under SEBI's framework (Circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018) using the standard Annexure XII-A format prescribed by the SEBI Operational Circular dated August 10, 2021. Companies classified as Large Corporates face additional obligations such as mandatory bond/quantum borrowings and incremental ESG disclosures. Since Venus Remedies does not meet the threshold, these extra compliance burdens do not apply to it. The disclosure was signed on 22nd April 2025 and submitted to both stock exchanges where the company is listed (BSE: 526953, NSE: VENUSREM).
This is a routine annual compliance filing with no direct impact on shareholders or the stock price. It simply confirms that Venus Remedies remains below the SEBI-defined size threshold for Large Corporate classification, meaning no incremental borrowing or disclosure obligations are triggered.